article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Indeed, since 2014, DPD facilitatedthe publication of 42 quarterly batches and dozens of stand-alone PSGs, plus three one-off batches of PSGs updated to align with recommendations in general guidance documents ( g. , Publishing virtually every GDUFA guidance and MAPP since 2014 to fulfill FDAs GDUFA commitments. 314.150(c).

FDA 144
article thumbnail

Developing an effective contamination control strategy

European Pharmaceutical Review

Although core to the new EU GMP Annex 1 1 – mentioned more than 50 times in the 2022 version of the document – contamination control strategies are not new. Early adopters started putting these strategies together around 20 years ago.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EMA sets out proposals to reform EU’s clinical trials framework

pharmaphorum

The broad strokes of the proposals are laid out in a document entitled Accelerating Clinical Trials in the EU (ACT EU) that lists priority actions that will be taken, including measures to allow greater use of innovative clinical trial designs.

article thumbnail

Five Lessons Learned About Antimicrobial Stewardship Metrics

IDStewardship

It may be derived from work completed inthe microbiology lab, unitsdispensed from the pharmacy, administrations performed by nurses, expenditures produced from drug purchases, documentation within any area of the electronic medical record, extraction from supplemental tools or data warehouses, and so much more.

article thumbnail

STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs

STAT

They were approved under the FDA accelerated pathway in 2009 and 2014, respectively, for treating a rare form of blood cancer. The  The company’s final study plan was submitted to the FDA in 2022 and is expected to be completed  by 2030 , according to FDA briefing documents published earlier this week.

FDA 100
article thumbnail

Legal requirement, ethical duty: How to develop compliant, useful lay summaries

pharmaphorum

536/2014, due to come into force in February next year. That’s why the GLSP document, which has been included in EudraLex Volume 10, is just as applicable in other markets, including the UK and US, as they are in the EU. “We New lay summary guidelines walk sponsors through their obligations under EU regulation No.

article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Keith Wilson is a former heart patient who has worked on a voluntary basis, over many years with various organisations and researchers, promoting Public and Patient involvement to enhance the clarity of documentation and participation in Research. Embedding the patient voice not only in research, but everything they do.